Physician profile
Timothy Paul Wright
NPI 1083667299
$2,632.90
in general payments reported to CMS, 2019-2025
36 companies · $593 in 2025
The $593 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $36.24 · 2021: $256 · 2022: $380 · 2023: $384 · 2024: $581 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,557.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $776.74 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Davol INC. | $258.23 | 2019-2021 | |
| Janssen Biotech, INC. | $136.21 | 2023-2024 | Stelara, Simponi, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $131.34 | 2019-2025 | Gattex |
| Regeneron Healthcare Solutions, INC. | $114.30 | 2022-2025 | Dupixent |
| Medtronic, INC. | $110.98 | 2021-2025 | Endoflip |
| Daiichi Sankyo INC. | $104.33 | 2019-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $81.70 | 2022-2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $79.78 | 2021-2022 | |
| Boston Scientific Corporation | $78.16 | 2023-2024 | Watchman Access System, Watchman Flx |
| Urogen Pharma, INC. | $78.02 | 2025 | |
| Lilly USA, LLC | $67.96 | 2023-2024 | Omvoh |
| Urovant Sciences INC | $50.47 | 2022 | |
| Smith+Nephew, INC. | $49.61 | 2019-2025 | Collagenase Santyl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.73 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $35.26 | 2024-2025 | Activ.A.C., Prevena, V.A.C.Ulta |
| Ardelyx, INC. | $35.18 | 2024-2025 | Ibsrela |
| Hologic Sales and Service, LLC | $35.09 | 2024 | Localizer, Trident Specimen Radiography System |
| Madrigal Pharmaceuticals | $32.44 | 2024-2025 | Rezdiffra, Resmetirom |
| Organogenesis INC. | $30.05 | 2021 | |
| Polynovo North America LLC | $28.29 | 2024 | Novosorb Btm |
| Molli Surgical (US) INC | $27.04 | 2023 | |
| Leica Microsystems INC. | $27.02 | 2025 | Neoprobe |
| Endo USA, INC. | $25.09 | 2025 | Xiaflex |
| Ferring Pharmaceuticals INC. | $24.01 | 2025 | Adstiladrin |
| Teleflex LLC | $23.33 | 2025 | Urolift |
| Baxter Healthcare | $17.66 | 2025 | Perclot |
| Intercept Pharmaceuticals, INC. | $17.25 | 2022 | |
| Calyxo, INC. | $16.85 | 2025 | Cvac Aspiration System |
| Sumitomo Pharma America, INC. | $16.24 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $15.03 | 2023 | |
| Ethicon US, LLC | $14.59 | 2024 | Echelon Flex |
| Convatec INC. | $13.38 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.29 | 2022 | |
| Vivus LLC | $11.28 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.